Differences between myeloperoxidase‑antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3‑ANCA associated vasculitis: A retrospective study from a single center in China

Wu, Ting; Shen, Cong; Zhong, Yong; Ooi, Joshua D.; Zhou, Yujun; Chen, Jinbiao; Meng, Ting; Xiao, Zhou; Lin, Wei; Ao, Xiang; Xiao, Xiangcheng; Zhou, Qiaoling; Xiao, Ping

doi:10.3892/etm.2021.9993

Cited by 5 publications

(2 citation statements)

References 44 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More studies are needed to clarify to mechanism of ANCA in IgAN. Existing studies had shown that there were differences in regional population distribution and clinical characteristics among AAV patients with different ANCA types [34][35][36][37]. Compared with MPO-ANCA-positive patients, PR3-ANCA-positive patients were younger, had fewer kidney involvements, and had more extrarenal manifestations [34,35].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity

Li,

Chen,

Chen

et al. 2023

Am J Nephrol

View full text Add to dashboard Cite

Objective: IgA nephropathy (IgAN) with serum Antineutrophil Cytoplasmic Autoantibody (ANCA) positivity is uncommon. This study analyzed the clinicopathologic features and prognosis of IgAN patients with serum ANCA positivity. Methods: 2864 IgAN patients were tested for ANCA by the indirect immunofluorescence assay and chemiluminescence immunoassay. Patients with serum ANCA positivity (n=85) were identified and their clinical, pathological and prognostic characteristics were analyzed. They were compared with ANCA negative IgAN patients (n=170) and ANCA-associated systemic vasculitis (AAV) with renal involvement patients (n=85) selected randomly. Result：2.97% (85/2864) of IgAN were ANCA positive and 4 patients were diagnosed as crescentic IgAN with ANCA positivity. The clinicopathological characteristics of ANCA-positive IgAN patients were comparable to ANCA-negative IgAN patients, but they had higher antinuclear antibodies (ANA) positive rates and lower levels of renal interstitial inflammation and less immune depositions than ANCA-negative IgAN patients. Compared with AAV patients, ANCA-positive IgAN patients were younger, fewer extrarenal manifestations, milder renal damage and more immune complexes depositions. The renal outcomes were similar between IgAN patients with and without ANCA positivity. Multivariate Cox analysis revealed that in IgAN patients with ANCA positivity, male, ANA positivity, higher serum creatinine and proteinuria, and more severe renal tubular atrophy/interstitial fibrosis were risk factors for adverse renal outcomes. Conclusion: The clinical, pathological features and prognosis of ANCA-positive IgAN patients were similar with ANCA-negative IgAN patients except for higher ANA positive rate, milder renal inflammation and less immune depositions. ANA positivity was an independent risk factor for adverse renal outcomes in ANCA-positive IgAN patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity

Li,

Chen,

Chen

et al. 2023

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…The GPA and MPA degenerative alterations in the glomeruli and tubulointerstitia were indistinguishable. Patients with MPO-AAV had considerably more risk of end-stage renal disease than those with PR3-AAV [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review

Habibi

Alesaeidi

Zahedi

et al. 2022

Biology

View full text Add to dashboard Cite

Background and aim: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease developed by autoantibody production against human neutrophilic granulocytes, including proteinase-3 (PR3) and myeloperoxidase (MPO). The management of AAV patients is difficult due to the multiorgan involvement, high rate of relapse, and complications of immunosuppressive agents that make it challenging. This study aims to investigate the efficacy and safety of rituximab (RTX) therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) subtypes. Method: The PubMed/Medline database was searched for any studies related to RTX therapy in ANCA-associated vasculitis (GPA and MPA subtypes), from inception to 1 August 2022, and proceeded in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Our search resulted in 1082 initial records. After the elimination of review papers, irrelevant studies, and non-English records, 223 articles were included, and the data related to the efficacy and safety of RTX therapy were extracted. Several randomized and non-randomized studies showed that RTX is an effective treatment option for patients with AAV. Most of the studies showed the very effective effect of RTX in controlling disease in AAV patients, including pediatrics, adults, and elderlies, although RTX cannot completely prevent relapse. However, maintenance therapy helps delay the disease’s relapse and causes sustained remission. Not only the licensed dose (375 mg/m2 intravenous per week for 4 weeks) could induce disease remission, but studies also showed that a single infusion of RTX could be effective. Although RTX could resolve many rare manifestations in AAV patients, there are few reports showing treatment failure. Additionally, few sudies have reported the unexpeted worsening of the disease after RTX administration. Generally, RTX is relatively safe compared to conventional therapies, but some serious adverse effects, mainly infections, cytopenia, hypogammaglobinemia, malignancy, and hypersensitivity have been reported. Conclusions: RTX is an effective and relatively safe therapeutic option for AAV. Studies on the evaluation of the safety profiles of RTX and the prevention of severe RTX-related side effects in AAV patients are required.

show abstract

Validation of the renal risk score for antineutrophil cytoplasmic antibody-associated glomerulonephritis in a Chinese population

et al. 2021

View full text Add to dashboard Cite

Differences between myeloperoxidase‑antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3‑ANCA associated vasculitis: A retrospective study from a single center in China

Cited by 5 publications

References 44 publications

Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity

Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review

Validation of the renal risk score for antineutrophil cytoplasmic antibody-associated glomerulonephritis in a Chinese population

Contact Info

Product

Resources

About